AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15732870 — intervention group
Group type: COMPARATOR
Intervention: BDX alone
Number of subjects: 13
Study 11157186 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal balloon protection during carotid stenting
Number of subjects: 8
Study 11157186 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 8
Study 8102913 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tiacrilast 3% hydrogel
Number of subjects: 32
Study 8102913 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 32
Study 2893778 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tulobuterol
Number of subjects: 0
Study 2893778 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg salbutamol
Number of subjects: 0
Study 2893778 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline
Number of subjects: 0
Study 2893778 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2-agonists during strong contraction
Number of subjects: 0
Study 2893778 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous beta 2-sympathomimetic treatment
Number of subjects: 0
Study 2893778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29436320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 85
Study 29436320 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR) therapy
Number of subjects: 85
Study 29436320 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 28387058 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 767
Study 28387058 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 767
Study 28387058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study 26271221 — intervention group
Group type: EXPERIMENTAL
Intervention: Water session (200 ml water with breakfast, 750 ml water over 2 hours)
Number of subjects: 52
Study 26271221 — intervention group
Group type: COMPARATOR
Intervention: Control session (no water after breakfast)
Number of subjects: 52
Study 23277532 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced heart rate of 80 b.p.m.
Number of subjects: 10
Study 23277532 — intervention group
Group type: COMPARATOR
Intervention: Paced heart rate of 60 b.p.m.
Number of subjects: 10
Study 21331651 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion cruciate substituting (PS) knee
Number of subjects: 95
Study 21331651 — intervention group
Group type: COMPARATOR
Intervention: High-flexion cruciate retaining (CR) knee
Number of subjects: 95
Study 18230798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoendocrine therapy
Number of subjects: 2732
Study 18230798 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 2732
Study 16879682 — intervention group
Group type: EXPERIMENTAL
Intervention: Millin modified retropubic prostatectomy
Number of subjects: 62
Study 16879682 — intervention group
Group type: COMPARATOR
Intervention: Classical transvesical prostatectomy
Number of subjects: 62
Study 14684712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 444
Study 14684712 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 444
Study 14684712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 444
Study 14684712 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fluoxetine and Nortriptyline)
Number of subjects: 444
Study 11195032 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic Ems salt solution
Number of subjects: 40
Study 11195032 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution
Number of subjects: 40
Study 9248588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of 50% glycerol
Number of subjects: 15
Study 9248588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 0.5% bupivacaine
Number of subjects: 15
Study 8340208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐design synthesis strategy
Number of subjects: 0
Study 3499246 — intervention group
Group type: EXPERIMENTAL
Intervention: 17/25/1 cold-adapted reassortant vaccine
Number of subjects: 170
Study 3499246 — intervention group
Group type: EXPERIMENTAL
Intervention: CR 59 cold-adapted reassortant vaccine
Number of subjects: 170
Study 31838405 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 556
Study 31838405 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib/gefitinib
Number of subjects: 556
Study 30566020 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (as a risk factor)
Number of subjects: 493519
Study 30566020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis for height
Number of subjects: 493519
Study 29178852 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-oriented post-test HIV counseling
Number of subjects: 711
Study 26267253 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS intervention
Number of subjects: 12
Study 26267253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 24035507 — intervention group
Group type: EXPERIMENTAL
Intervention: CPRmeter feedback device (group G)
Number of subjects: 144
Study 20797696 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech task
Number of subjects: 60
Study 20797696 — intervention group
Group type: COMPARATOR
Intervention: Reading task
Number of subjects: 60
Study 19767092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense paclitaxel (80 mg/m²; 1-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=312
Number of subjects: 631
Study 19767092 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen: Paclitaxel (180 mg/m²; 3-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=319
Number of subjects: 631
Study 19767092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense regimen
Number of subjects: 631
Study 19767092 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 631
Study 17224859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose transdermal estradiol (0.014 mg/d)
Number of subjects: 417
Study 17224859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 15097957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of narrowband UVB plus cream PUVA
Number of subjects: 30
Study 15097957 — intervention group
Group type: COMPARATOR
Intervention: Cream PUVA
Number of subjects: 30
Study 15097957 — intervention group
Group type: COMPARATOR
Intervention: Narrowband UVB
Number of subjects: 30
Study 9525297 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy combined with anti-tuberculosis chemotherapy (n=17)
Number of subjects: 34
Study 9525297 — intervention group
Group type: COMPARATOR
Intervention: Anti-tuberculosis chemotherapy only (n=17)
Number of subjects: 34
Study 8083624 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Pulsating Stimulation (VPS)
Number of subjects: 0
Study 8083624 — intervention group
Group type: COMPARATOR
Intervention: Control (no VPS)
Number of subjects: 0
Study 2979691 — intervention group
Group type: EXPERIMENTAL
Intervention: Caved-S two tablets twice daily
Number of subjects: 95
Study 2979691 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg at night
Number of subjects: 95
Study 2979691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Caved-S + Ranitidine)
Number of subjects: 95
Study 2979691 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 95
Study 2979691 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-maintenance therapy
Number of subjects: 95
Study 28958744 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department/home environmental control intervention
Number of subjects: 0
Study 28958744 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver worry about medication side effects
Number of subjects: 0
Study 28958744 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 0
Study 28958744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or more primary care provider asthma visits within the past 3 months
Number of subjects: 0
Study 28958744 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control assessed during fall or spring season
Number of subjects: 0
Study 26990147 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Lactobacillus rhamnosus GG
Number of subjects: 59
Study 26990147 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated Lactobacillus rhamnosus GG
Number of subjects: 59
Study 26990147 — intervention group
Group type: COMPARATOR
Intervention: Control juice (placebo)
Number of subjects: 59
Study 26990147 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of HRV load with symptom scores
Number of subjects: 59
Study 25424821 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVpur Junior
Number of subjects: 0
Study 25424821 — intervention group
Group type: COMPARATOR
Intervention: Havrix 720 Junior
Number of subjects: 0
Study 25424821 — intervention group
Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 0
Study 22965298 — intervention group
Group type: EXPERIMENTAL
Intervention: JASPER treatment (30 min, twice weekly for 12 weeks)
Number of subjects: 0
Study 22965298 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (30 h of ABA-based therapy per week)
Number of subjects: 0
Study 19910882 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Management Intervention
Number of subjects: 1202
Study 19910882 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1202
Study 18585531 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 433
Study 18585531 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 433
Study 18585531 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 433
Study 16958964 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular pattern of trial medication intake
Number of subjects: 0
Study 16958964 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional prescribed medication
Number of subjects: 0
Study 16958964 — intervention group
Group type: EXPERIMENTAL
Intervention: Not smoking
Number of subjects: 0
Study 12505938 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-N2O anesthesia
Number of subjects: 36
Study 12505938 — intervention group
Group type: COMPARATOR
Intervention: Control (no propofol, no N2O)
Number of subjects: 36
Study 10364996 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero deadspace tracheal tube (ZEDS‐TT)
Number of subjects: 11
Study 10364996 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen tracheal tube
Number of subjects: 11
Study 8644687 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 8
Study 8644687 — intervention group
Group type: COMPARATOR
Intervention: Tallow
Number of subjects: 8
Study 1899797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyquinoline ointment
Number of subjects: 0
Study 1899797 — intervention group
Group type: COMPARATOR
Intervention: Desitin or A & D ointment (Control)
Number of subjects: 0
Study 6239292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (200 micrograms) plus ipratropium bromide (80 micrograms) delivered by standard aerosol inhaler
Number of subjects: 12
Study 6239292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (200 micrograms) plus ipratropium bromide (80 micrograms) delivered by inhaler with extension tube spacer
Number of subjects: 12
Study 6239292 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 30624371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous aerobic exercise training (AET)
Number of subjects: 18
Study 30624371 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (sedentary women, n = 19)
Number of subjects: 18
Study 28925580 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention including nutrition, stimulation, sanitation, and hygiene
Number of subjects: 511
Study 28925580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 511
Study 26351971 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (100 mg/kg) and Budesonide (0.25 mg/kg)
Number of subjects: 265
Study 26351971 — intervention group
Group type: COMPARATOR
Intervention: Surfactant only (100 mg/kg)
Number of subjects: 265
Study 24457276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (6 mg bolus injection before PCI and 6 mg/hour infusion for 24 hours)
Number of subjects: 62
Study 24457276 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 62
Study 23032159 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 304
Study 23032159 — intervention group
Group type: COMPARATOR
Intervention: MenC‐CRM 197
Number of subjects: 304
Study 20846797 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 0
Study 17182160 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI patients
Number of subjects: 30
Study 17182160 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 15515998 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of both visceral and parietal peritoneum (Group A)
Number of subjects: 360
Study 15515998 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of only visceral peritoneum (Group B)
Number of subjects: 360
Study 15515998 — intervention group
Group type: COMPARATOR
Intervention: Closure of both visceral and parietal peritoneum (Group C)
Number of subjects: 360
Study 11559453 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/EE (drospirenone 3 mg and ethinyl estradiol 30 microg)
Number of subjects: 82
Study 11559453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 11559453 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/EE
Number of subjects: 82
Study 9760324 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken broth (CB: 109.5 mmol/l Na, 25.3 mmol/l K)
Number of subjects: 30
Study 9760324 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken noodle soup (Soup: 333.8 mmol/l Na, 13.7 mmol/l K)
Number of subjects: 30
Study 9760324 — intervention group
Group type: COMPARATOR
Intervention: Water (H2O)
Number of subjects: 30
Study 9760324 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate‐electrolyte drink (CE: 16.0 mmol/l Na, 3.3 mmol/l K)
Number of subjects: 30
Study 9760324 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte drink (CE)
Number of subjects: 30
Study 9760324 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken broth (CB) and Chicken noodle soup (Soup)
Number of subjects: 30
Study 7826904 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFp (Cyclophosphamide-Methotrexate-Fluorouracil plus low-dose continuous prednisone)
Number of subjects: 1601
Study 7826904 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFp plus surgical oophorectomy
Number of subjects: 1601
Study 7826904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoendocrine therapy (CMFp plus tamoxifen)
Number of subjects: 1601
Study 7826904 — intervention group
Group type: EXPERIMENTAL
Intervention: p + T (prednisone plus tamoxifen)
Number of subjects: 1601
Study 3377464 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (500 mg each) administered intravenously
Number of subjects: 6
Study 3377464 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (500 mg each) administered intraperitoneally
Number of subjects: 6
Study 3377464 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 6
Study 3377464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilastatin
Number of subjects: 6
Study 31233464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m/dose)
Number of subjects: 20
Study 31233464 — intervention group
Group type: COMPARATOR
Intervention: Vincristine
Number of subjects: 20
Study 31233464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 20
Study 28641838 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT for 6 months
Number of subjects: 3773
Study 28641838 — intervention group
Group type: COMPARATOR
Intervention: DAPT for 18 months
Number of subjects: 3773
Study 25026950 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with a bipolar virtual patient (VP)
Number of subjects: 67
Study 25026950 — intervention group
Group type: COMPARATOR
Intervention: Completion of a video-teaching module
Number of subjects: 67
Study 24156500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition training for mid-level providers (MLPs) using WHO guidelines; duration: 6 months.
Number of subjects: 800
Study 21564041 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 75
Study 21564041 — intervention group
Group type: COMPARATOR
Intervention: Flexible fibreoptic bronchoscope
Number of subjects: 75
Study 19235866 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-alpha-2b (10 MU) with ribavirin (RBV)
Number of subjects: 200
Study 19235866 — intervention group
Group type: COMPARATOR
Intervention: Standard dose interferon-alpha-2b (6 MU) with ribavirin (RBV)
Number of subjects: 200
Study 15961759 — intervention group
Group type: EXPERIMENTAL
Intervention: MEC plus lintuzumab (12 mg/m2)
Number of subjects: 191
Study 15961759 — intervention group
Group type: COMPARATOR
Intervention: MEC alone
Number of subjects: 191
Study 11988245 — intervention group
Group type: EXPERIMENTAL
Intervention: Whispered voice test
Number of subjects: 32656
Study 11988245 — intervention group
Group type: EXPERIMENTAL
Intervention: Whispered voice test after wax removal
Number of subjects: 32656
Study 11988245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid ownership
Number of subjects: 32656
Study 11988245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid usage
Number of subjects: 32656
Study 9579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Servo Ventilator 300
Number of subjects: 20
Study 9579266 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP Bird
Number of subjects: 20
Study 9579266 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE 2000 Neonatal Ventilator
Number of subjects: 20
Study 9579266 — intervention group
Group type: COMPARATOR
Intervention: SLE 2000
Number of subjects: 20
Study 8749876 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol administration during tilt test
Number of subjects: 44
Study 2702512 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lignocaine (40 mg)
Number of subjects: 8
Study 2702512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Number of subjects: 8
Study 139671 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol (an anabolic steroid), orally active, duration 4 months
Number of subjects: 0
Study 139671 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31373901 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based preoperative and postoperative patient care education
Number of subjects: 305
Study 31373901 — intervention group
Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 305
Study 28031707 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (B/F) 320/9 μg, twice daily
Number of subjects: 1571
Study 25237170 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture anchor technique
Number of subjects: 45
Study 25237170 — intervention group
Group type: COMPARATOR
Intervention: Suture bridge technique
Number of subjects: 45
Study 23507459 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative information about college drinking
Number of subjects: 80
Study 23507459 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no normative information)
Number of subjects: 80
Study 21520106 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative crooked noses
Number of subjects: 40
Study 21520106 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative crooked noses
Number of subjects: 40
Study 21520106 — intervention group
Group type: COMPARATOR
Intervention: Normal noses
Number of subjects: 40
Study 19371522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (100 microg)
Number of subjects: 44
Study 19371522 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (10 mg)
Number of subjects: 44
Study 16896118 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (administered bimonthly)
Number of subjects: 350
Study 16896118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 350
Study 15019669 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 35
Study 15019669 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 35
Study 11491177 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccines (split product and surface antigen vaccines)
Number of subjects: 0
Study 11491177 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral drugs (amantadine and rimantadine)
Number of subjects: 0
Study 11491177 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiviral agents targeting influenza neuraminidase
Number of subjects: 0
Study 9396433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (0.6 mL of 10,250 anti-Xa IU/mL)
Number of subjects: 354
Study 9396433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 9396433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 354
Study 7970790 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin end‐point titration based immunotherapy
Number of subjects: 30
Study 7970790 — intervention group
Group type: COMPARATOR
Intervention: Prick testing based immunotherapy
Number of subjects: 30
Study 7970790 — intervention group
Group type: COMPARATOR
Intervention: Scratch testing based immunotherapy
Number of subjects: 30
Study 3581636 — intervention group
Group type: EXPERIMENTAL
Intervention: Slo‐bid Gyrocaps
Number of subjects: 15